Lurasidone for schizophrenia: What's different?

Expert Review of Neurotherapeutics

Volumn 12, Issue 3, 2012, Pages 265-273

  Kantrowitz, Joshua T ^a,b   Citrome, Leslie ^c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

antipsychotic; cognition; lurasidone; metabolic syndrome; schizophrenia

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; DILTIAZEM; HALOPERIDOL; ILOPERIDONE; KETOCONAZOLE; LITHIUM; LURASIDONE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RIFAMPICIN; RISPERIDONE; ZIPRASIDONE;

AGITATION; AKATHISIA; CHOLESTEROL BLOOD LEVEL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; EXTRAPYRAMIDAL SYMPTOM; FOOD DRUG INTERACTION; HUMAN; INSOMNIA; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; ISOINDOLES; SCHIZOPHRENIA; THIAZOLES;

EID: 84857991752     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.7     Document Type: Review

References (53)

1. Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13(9), 1102-1107 (2007). (Pubitemid 47517511)
2. Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses 4(3), 189-200 (2010).
3. Di Forti M, Lappin JM, Murray RM. Risk factors for schizophrenia - all roads lead to dopamine. Eur. Neuropsychopharmacol. 17(Suppl. 2), S101-S107 (2007).
4. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1253 (2005).
5. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
6. McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163(4), 600-610 (2006). (Pubitemid 44464569)
7. Jones P, Barnes T, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63(10), 1079-1087 (2006). (Pubitemid 44498387)
8. Davis J, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60(6), 553-564 (2003).
9. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 70(5), 627-643 (2009).
10. Allison D, Mentore J, Heo M et al. Antipsychotic induced weight gain: a comprehensive literature synthesis. Am J. Psychiatry 156(11), 1686-1696 (1999). (Pubitemid 29517559)
11. Kantrowitz J, Citrome L. Olanzapine: review of safety 2008. Expert Opin. Drug Saf. 7(6), 761-769 (2008).
12. Komossa K, Rummel-Kluge C, unger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 4, CD006627 (2009).
13. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst. Rev. 12, CD006629 (2010).
14. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin. Pharmacother. doi:10.151 7/14656566.2011.626767 (2011) (Epub ahead of print).
15. Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence 2(4), 261-271 (2008).
16. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad. Med. 123(2), 153-162 (2011).
17. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin. Schizophr. Relat. Psychoses 4(4), 251-257 (2011).
18. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int. J. Clin. Pract. 65(2), 189-210 (2011).
19. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther. Clin. Risk Manag. 7, 239-250 (2011).
20. Owen RT. Lurasidone: a new treatment option for schizophrenia. Drugs Today 47(11), 807-816 (2011).
21. Meltzer HY, Cucchiaro J, Silva R et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 168(9), 957-967 (2011).
22. Potkin S, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr. Res. 132(2-3), 101-107 (2011).
23. Ishibashi T, Horisawa T, Tokuda K et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 334(1), 171-181 (2010).
24. Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin. Drug Metab. Toxicol. 7(7), 829-846 (2011).
25. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin. Investig. Drugs 18(11), 1-12 (2009).
26. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 35(3), 549-562 (2009).
27. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 9(10 Suppl. 11), 6-14 (2004). (Pubitemid 39473434)
28. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J. Pharmacol. Exp. Ther. 338(2), 605-614 (2011).
29. Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3), 519-526 (2003).
30. Preskorn S, Chiu YY, Sarubbi D, Ogasa M, Cucchiaro J, Loebel A. Lurasidone pharmacokinetics: assessment of potential for drug-drug interactions. Neuropsychopharmacology 35(Suppl. 1), S395 (2010).
31. Gandelman K, Alderman JA, Glue P et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J. Clin. Psychiatry 70(1), 58-62 (2009).
32. Chiu YY, Preskorn S, Sarubbi D, Cucchiaro J, Loebel A. Effect of food on lurasidone absorption. Presented at: NCDEU Meeting. Boca Raton, FL, USA, 14-17 June 2010.
33. Guay DR. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. Consult. Pharm. 26(8), 579-582 (2011).
34. Newcomer J, Loebel A, Pikalov A, Sarocco P, Cucchiaro J, Siu C. Impact of lurasidone and olanzapine on Framingham ten-year coronary heart disease risk estimate in schizophrenia. Neuropsychopharmacology 35(Suppl. 1), S335-S336 (2010).
35. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837-1847 (1998). (Pubitemid 28213628)
36. Loebel A, Cucchiaro J, Pikalov A et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, PEARL 3 trial. Neuropsychopharmacology 35(Suppl. 1), S313-S314 (2011).
37. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 127(1-3), 188-194 (2011).
38. Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am. J. Psychiatry 168(9), 947-956 (2011).
39. Stahl S, Cucchiaro J, Simonelli D, Loebel A. Long-term safety and tolerability of lurasidone in subjects with schizophrenia: results of a 6-month, open-label study. Neuropsychopharmacology 35(Suppl. 1), S316-S317 (2010).
40. Citrome L, Cucchiaro J, Sarma K et al. Long-term safety and tolerability of lurasidone in schizophrenia or schizoaffective disorder: a 12-month, double-blind, active-controlled study. Presented at: 164th Annual Meeting of the American Psychiatric Association. Honolulu, HI, USA, 14-18 May 2011.
41. Woodberry KA. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry 165(5), 579-587 (2008). (Pubitemid 351705334)
42. Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episodeschizophrenia: is it a practice effect? Arch. Gen. Psychiatry 64(10), 1115-1122 (2007). (Pubitemid 47529336)
43. Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. The novel antipsychotic drug lurasidone enhances NMDA receptor-mediated synaptic responses. Mol. Pharmacol. 81(2), 113-119 (2012).
44. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res. Bull. 83(3-4), 108-121 (2010).
45. Nuechterlein KH, Green MF, Kern RS et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165(2), 203-213 (2008). (Pubitemid 351704520)
46. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am. J. Psychiatry 163, 426-432 (2006). (Pubitemid 44469384)
47. Harvey PD, Hsu J, Cucchiaro J et al. Cognitive performance in patients with acute schizophrenia treated with lurasidone: a double blind, placebo controlled trial. Presented at: 164th Annual Meeting of the American Psychiatric Association. Honolulu, HI, USA, 14-18 May 2011.
48. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J. Clin. Exp. Neuropsychol. 31(7), 848-859 (2009).
49. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin. Pharmacother. 10(12), 1917-1928 (2009).
50. [No authors listed]. Lurasidone (Latuda) for schizophrenia. Med. Lett. Drugs Ther. 53(1358), 13-14 (2011).
51. Nakamura M, Ogasa M, Guarino J et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 70(6), 829-836 (2009).
52. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 216(4), 451-473 (2011).
53. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr. Dis. Treat. 2(4), 427-443 (2006). (Pubitemid 46321873)